These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36385395)

  • 1. A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease.
    De Bartolo MI; Vivacqua G; Belvisi D; Mancinelli R; Fabbrini A; Manzo N; Costanzo M; Leodori G; Conte A; Fabbrini G; Morini S; Berardelli A
    Ann Neurol; 2023 Mar; 93(3):446-459. PubMed ID: 36385395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.
    Cressatti M; Juwara L; Galindez JM; Velly AM; Nkurunziza ES; Marier S; Canie O; Gornistky M; Schipper HM
    Mov Disord; 2020 Mar; 35(3):468-477. PubMed ID: 31800144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
    Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease.
    Cao Z; Wu Y; Liu G; Jiang Y; Wang X; Wang Z; Feng T
    Neurosci Lett; 2019 Mar; 696():114-120. PubMed ID: 30579996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.
    Angius F; Mocci I; Ercoli T; Loy F; Fadda L; Palmas MF; Cannas G; Manzin A; Defazio G; Carta AR
    J Neurol; 2023 Nov; 270(11):5613-5621. PubMed ID: 37552278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of salivary biomarkers in Parkinson's disease.
    De Bartolo MI; Belvisi D; Mancinelli R; Costanzo M; Caturano C; Leodori G; Berardelli A; Fabbrini G; Vivacqua G
    Neural Regen Res; 2024 Dec; 19(12):2613-2625. PubMed ID: 38595280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.
    Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P
    Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
    Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
    Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
    Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
    Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.